24/7 Market News Snapshot 04 August, 2025 – Artelo Biosciences, Inc. Common Stock (NASDAQ:ARTL)

August 4, 2025

DENVER, Colo., 04 August, 2025 (www.247marketnews.com) – (Nasdaq:ARTL) are discussed in this article.
Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical firm, is currently witnessing a notable bullish trend, with shares reaching approximately $11.295 in pre-market trading, reflecting a significant increase of around 10.74% from the previous session’s close of $10.200. This upward movement signals a surge in investor enthusiasm and positive market sentiment towards the company’s growth potential. Current trading volume is robust at 520.70K, demonstrating heightened interest among investors in the stock, which may be indicative of a strong upward momentum.

In a strategic development, Artelo has also initiated a pioneering initiative to incorporate cryptocurrency into its treasury management framework. The company has secured a securities purchase agreement for an at-the-market private investment in public equity (PIPE) transaction, targeting to raise approximately $9.475 million. This innovative funding will enable Artelo to adopt Solana (SOL), a leading cryptocurrency, as a reserve asset.

As part of this agreement, Artelo plans to issue 906,687 shares of common stock, along with warrants allowing investors to acquire additional shares at specified prices. This strategic move positions Artelo as the first publicly traded pharmaceutical company to utilize SOL in its treasury management.

Enhancing the initiative is Bartosz Lipiński, a seasoned investor and former Head of Engineering at Solana Labs, who joins as a technical partner through his firm, CUBE. Lipiński highlighted Artelo’s proactive approach in adopting SOL, asserting that it underscores a commitment to sustainable growth and operational resilience.

Gregory D. Gorgas, Artelo’s Chief Executive Officer, affirmed that leveraging SOL offers a forward-looking strategy to enhance shareholder value while navigating an increasingly complex financial landscape. With the anticipated completion of the PIPE transaction set for early August, subject to customary conditions, Artelo is poised for a pivotal advancement in both its therapeutic development and financial strategy.

Related news for (ARTL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.